nach oben

NanoEthics

Erschienen in:

01.04.2014 | Original Paper

The Clinical Research of Nanomedicine: A New Ethical Challenge?

verfasst von: Urban Wiesing, Jens Clausen

Erschienen in: NanoEthics | Ausgabe 1/2014

Einloggen

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config

KI-gestützte Suche

Aus

Abtract

Nanomedicine promises unprecedented innovations for diagnosis and therapy as well as for predicting and preventing diseases. On the other hand it raises fears linked to new and unknown characteristics of nanoscale materials. Both, promises and fears, are closely linked to the realm of uncertainty. To a large extent it is currently not known which expectations could become reality and which suspected adverse events might come true. Medicine is quite familiar with decision-making under uncertainty. Rules and regulations for clinical research have been developed to reduce possible harm for research participants without abandoning necessary investigations. Here we examine whether clinical research trials of nanomedicine need new regulations and conclude that the established rules should suffice.

Vorheriger Artikel Metaphors in Nanomedicine: The Case of Targeted Drug Delivery

Nächster Artikel Characteristics, Properties and Ethical Issues of Carbon Nanotubes in Biomedical Applications

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

über 102.000 Bücher
über 537 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Finance + Banking
Management + Führung
Marketing + Vertrieb
Maschinenbau + Werkstoffe
Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Springer Professional "Wirtschaft"

Online-Abonnement

Mit Springer Professional "Wirtschaft" erhalten Sie Zugriff auf:

über 67.000 Bücher
über 340 Zeitschriften

aus folgenden Fachgebieten:

Bauwesen + Immobilien
Business IT + Informatik
Finance + Banking
Management + Führung
Marketing + Vertrieb
Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Jetzt informieren

The risk is then calculated by multiplying the amount of damage with the probability of occurrence. In a rational decision, the option with the lowest risk would be selected

In Parexel’s pharmacological testing institute at Northwick Park Hospital in London on 13 March 2006, the monoclonal antibody TGN1412 was tested on humans for the first time. TGN1412 is a strong agonist for the CD28 receptor of the immune system’s T cells. Initially, there was hope to treat chronic lymphocytic leukemia and autoimmune diseases with the drug. It was developed by order of the start-up company TeGenero of the company Boehringer Ingelheim. Paraxel also worked on behalf of TeGenero. The previous animal experiments had shown no evidence of adverse effects.

Of the eight healthy subjects, six received the active treatment, two placebo. A few hours after the injection, all six subjects who had received the active treatment experienced a severe immunological reaction known as the cytokine release syndrome that resulted in significant, life-threatening health problems. They suffered from multi-organ failure and some had to be treated in intensive care for weeks. All six subjects survived, but with significant damage to their health.

Despite the fact that the substance class of monoclonal antibodies is not new (17 substances of this kind in Europe have already been approved) as well as the existing regulations, it still had these serious, life-threatening effects.

The sequential application to one person was not performed; all six subjects received the drug at the same time, while two individuals received a placebo.

Anonymous (2008) The same old story. Nat Nanotechnol 3:S. 697

Alexiou C (2013) Nanomedicine. innovative applications in medicine. HNO 61:197–201CrossRef

Allhoff F (2009) Risk, precaution, and emerging technologies. Stud Ethics Law Technol 3:1–27CrossRef

Allhoff F, Lin P, Moore D (2010) What is nanotechnoliogy and why does it matter? From science to ethics. Wiley-Blackwell, West SussexCrossRef

Arvizo RR, Bhattacharyya S, Kudgus RA, Giri K, Bhattacharya R, Mukherjee P (2012) Intrinsic therapeutic applications of noble metal nanoparticles: past, present and future. Chem Soc Rev 41:2943–2970

Berger F, Gevers S, Siep L, Weltring K-M (2008) Ethical, legal and social aspects of brain-implants using nano-scale materials and techniques. Nanoethics 2:241–249CrossRef

Commission E (2006) Nanomedicine: naotechnology for health. european technology platform—strategic research agenda for nanomedicine. Office for Official Publications of the European Communities, Luxembourg

DeVille KA (2008) Law, regulation and the medical use of nanotechnology. In: Jotterand F (ed) Emerging conceptual, ethical and policy issues in bionanotechnology. Springer, Berlin, pp 181–200

Drexler E (1987) Engines of creation—the coming era of nanotechnology. Anchor, New York

10.

Dresser R (2012) Building an ethical foundation for first-in-human nanotrials. J Law Med Ethics 40:802–808

11.

Duncan R, Gaspar R (2011) Nanomedicine(s) under the microscope. Mol Pharm 8:2101–2141CrossRef

12.

EGE (2007) Opinion 21 on the ethical aspects of nanomedicine. European Communities’ Publications Office, Luxembourg

13.

Emanuel EJ, Wendler D, Grady C (2000) What makes clinical research ethical? JAMA 283:2701–2711CrossRef

14.

Etheridge ML, Campbell SA, Erdman AG, Haynes CL, Wolf SM, McCullough J (2013) The big picture on nanomedicine: the state of investigational and approved nanomedicine products. Nanomedicine 9:1–14CrossRef

15.

Fatehi L, Wolf SM, McCullough J, Hall R, Lawrenz F, Kahn JP, Jones C, Campbell SA, Dresser RS, Erdman AG, Haynes CL, Hoerr RA, Hogle LF, Keane MA, Khushf G, King NM, Kokkoli E, Marchant G, Maynard AD, Philbert M, Ramachandran G, Siegel RA, Wickline S (2012) Recommendations for nanomedicine human subjects research oversight: an evolutionary approach for an emerging field. J Law Med Ethics 40:716–750

16.

Gordijn B (2005) Nanoethics: from utopian dreams and apocalyptic nightmares towards a more balanced view. Sci Eng Ethics 11:521–533CrossRef

17.

Grunwald A (2008) Auf dem Weg in eine nanotechnologische Zukunft: Philosophisch-ethische Fragen. Alber, Freiburg

18.

Grunwald A (2012) Responsible nanobiotechnology: philosophy and ethics. Pan Stanford, SingaporeCrossRef

19.

Hall RM, Sun T, Ferrari M (2012) A portrait of nanomedicine and its bioethical implications. J Law Med Ethics 40:763–779

20.

Hansson SO (2006) Great uncertainty about small things. In: Schummer J, Baird D (eds) Nanotechnology challenges—implications for philosophy, ethics and society. World Scientific Publishing, Singapur, pp 315–325CrossRef

21.

Hong Z, Zhang P, He C, Qiu X, Liu A, Chen L, Chen X, Jing X (2005) Nano-composite of poly(L-lactide) and surface grafted hydroxyapatite: mechanical properties and biocompatibility. Biomaterials 26:6296–6304CrossRef

22.

Hunziker P (2013) Nanomedicine: the use of nano-scale science for the benefit of the patient. Basel, CLINAM—European Foundation for Clinical Nanomedicine www.clinam.org

23.

Iancu C, Mocan L (2011) Advances in cancer therapy through the use of carbon nanotube-mediated targeted hyperthermia. Int J Nanomedicine 6:1675–1684CrossRef

24.

Jömann N, Ach JS (2006) Ethical implications of nanobiotechnology—state-of-the-art survey of ethical issues related to nanobiotechnology. In: Ach JS, Siep L (eds) Nano-bio-ethics. ethical and social dimensions of nanobiotechnology. LIT, Berlin, pp 13–62

25.

Juliano R (2013) Nanomedicine: is the wave cresting? Nat Rev Drug Discov 12:171–172CrossRef

26.

Kermisch C (2012) Do new ethical issues arise at each stage of nanotechnological development? Nanoethics 6:29–37CrossRef

27.

King NM (2012) Nanomedicine first-in-human research: challenges for informed consent. J Law Med Ethics 40:823–830

28.

Mastroianni AC (2006) Liability regulation and policy in surgical innovation: the cutting edge of research and therapy. Health Matrix Cleve 16:351–442

29.

Merkel R et al (2007) Intervening in the brain: changing psyche and society. Springer, Berlin

30.

Müri W (1986) Der Arzt im Altertum. Griechische und lateinische Quellenstücke von Hippokrates bis Galen mit der Übertragung ins Deutsche. Wiss. Buchgesellschaft, Darmstadt

31.

Nordmann A (2007) If and then: a critique of speculative nanoethics. Nanoethics 1:31–46CrossRef

32.

Oberdörster G (2010) Safety assessment for nanotechnology and nanomedicine: concepts of nanotoxicology. J Intern Med 267:89–105CrossRef

33.

Resnik DB (2007) Beyond post-marketing research and MedWatch: long-term studies of drug risks. Drug Des Devel Ther 1:1–5

34.

Resnik DB (2012) Responsible conduct in nanomedicine research: environmental concerns beyond the common rule. J Law Med Ethics 40:848–855

35.

Resnik DB, Tinkle SS (2007) Ethical issues in clinical trials involving nanomedicine. Contemp Clin Trials 28:433–441CrossRef

36.

Schermer M (2009) The mind and the machine. on conceptual and moral implications of brain-machine interaction. Nanoethics 3:217–230CrossRef

37.

Siep L (2008) Ethical problems of nanobiotechnology. In: Ach JS, Lüttenberg B (eds) Nanobiotechnology. Nanomedicine and Human Enhancement. LIT, Berlin, pp 17–26

38.

SRU (2011) Vorsorgestrategien für Nanomaterialien: Sondergutachten des Sachverständigenrats für Umweltfragen

39.

Suyatin DB, Wallman L, Thelin J, Prinz CN, Jorntell H, Samuelson L, Montelius L, Schouenborg J (2013) Nanowire-based electrode for acute in vivo neural recordings in the brain. PLoS One 8:e56673CrossRef

40.

Swierstra T, Rip A (2007) Nano-ethics as NEST-ethics: patterns of moral argumentation about new and emerging technology. Nanoethics 1:3–20CrossRef

41.

Toellner R (1990) Problemgeschichte: Entstehung der Ethik-Kommissionen. In: Toellner R (ed) Die Ethik-Kommission in der Medizin: Problemgeschichte, Aufgabenstellung, Arbeitsweise, Rechtsstellung und Organisationsformen Medizinischer Ethik-Kommissionen. Gustav Fischer, Stuttgart, pp 3–18

42.

Tran LA, Wilson LJ (2011) Nanomedicine: making controllable magnetic drug delivery possible for the treatment of breast cancer. Breast Cancer Res 13:303CrossRef

43.

Wagner V et al (2006) The emerging nanomedicine landscape. Nat Biotechnol 24:1211–1217CrossRef

44.

Wieland W (2004) Diagnose. Überlegungen zur Medizintheorie. Hoof, Warendorf

45.

Wiesing U (1995) Kunst oder Wissenschaft? Konzeptionen der Medizin in der deutschen Romantik. Frommann-Holzboog, Stuttgart-Bad Cannstatt

46.

Wolf SM (2012) Introduction: the challenge of nanomedicine human subjects research: protecting participants, workers, bystanders, and the environment. J Law Med Ethics 40:712–715

Titel: The Clinical Research of Nanomedicine: A New Ethical Challenge?
verfasst von: Urban Wiesing
Jens Clausen
Publikationsdatum: 01.04.2014
Verlag: Springer Netherlands
Erschienen in: NanoEthics / Ausgabe 1/2014
Print ISSN: 1871-4757
Elektronische ISSN: 1871-4765
DOI: https://doi.org/10.1007/s11569-014-0191-0

Springer Professional

Abtract

Bitte loggen Sie sich ein, um Zugang zu Ihrer Lizenz zu erhalten.

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Springer Professional "Wirtschaft"

Weitere Artikel der Ausgabe 1/2014

Metaphors in Nanomedicine: The Case of Targeted Drug Delivery

Is There a Moral Obligation to Develop Brain Implants Involving NanoBionic Technologies? Ethical Issues for Clinical Trials

Valuing Values: Better Public Engagement on Nanotechnology Demands a Better Understanding of the Diversity of Publics

Characteristics, Properties and Ethical Issues of Carbon Nanotubes in Biomedical Applications

Exploring Societal and Ethical Views of Nanotechnology REUs

Making Better Sense of Animal Disenhancement: A Reply to Henschke